市場調査レポート
商品コード
1623737

プレシジョン免疫腫瘍学の市場規模、シェア、成長分析、がんタイプ別、治療タイプ別、バイオマーカー別、最終用途別、地域別 - 産業予測、2025~2032年

Precision Immuno-Oncology Market Size, Share, Growth Analysis, By Cancer Type (Lung Cancer, Breast Cancer), By Treatment Type (Checkpoint Inhibitors, Car T Cell Therapy), By Biomarker, By End Use, By Region - Industry Forecast 2025-2032


出版日
発行
SkyQuest
ページ情報
英文 157 Pages
納期
3~5営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.96円
プレシジョン免疫腫瘍学の市場規模、シェア、成長分析、がんタイプ別、治療タイプ別、バイオマーカー別、最終用途別、地域別 - 産業予測、2025~2032年
出版日: 2024年12月25日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3~5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

プレシジョン免疫腫瘍学の世界市場規模は、2023年に606億5,000万米ドルと評価され、2024年の672億米ドルから2032年には1,526億5,000万米ドルに成長し、予測期間(2025-2032年)のCAGRは10.8%で成長する見通しです。

プレシジョン免疫腫瘍学は、患者の遺伝子プロファイル、腫瘍特性、免疫反応を考慮したオーダーメイド治療に焦点を当てた、がん治療の先駆的アプローチとして急速に普及しています。この個別化戦略は治療効果を高めるだけでなく、従来の治療法に比べて副作用を最小限に抑え、長期的な寛解への希望をもたらします。高度な診断は、がん細胞上の特異的な遺伝子変異やタンパク質を同定し、標的を絞った介入を可能にする上で重要な役割を果たします。臨床試験では、特に治療抵抗性のがん患者において有望な結果が示されており、患者の反応が顕著であることが示されています。この分野では、製薬会社がプレシジョン免疫腫瘍学の変革の可能性を認識するにつれて多額の投資が行われており、がん治療の進化における重要なマイルストーンとなり、市場における有望な将来性を浮き彫りにしています。

目次

イントロダクション

  • 調査の目的
  • 調査範囲
  • 定義

調査手法

  • 情報調達
  • 二次データと一次データの方法
  • 市場規模予測
  • 市場の前提条件と制限

エグゼクティブサマリー

  • 世界市場の見通し
  • 供給と需要の動向分析
  • セグメント別機会分析

市場力学と見通し

  • 市場概要
  • 市場規模
  • 市場力学
    • 促進要因と機会
    • 抑制要因と課題
  • ポーターの分析

主な市場の考察

  • 重要成功要因
  • 競合の程度
  • 主な投資機会
  • 市場エコシステム
  • 市場の魅力指数(2024年)
  • PESTEL分析
  • マクロ経済指標
  • バリューチェーン分析
  • 価格分析
  • 技術分析
  • 特許分析
  • パイプライン製品の分析
  • ケーススタディ分析

プレシジョン免疫腫瘍学市場規模:がんタイプ別

  • 市場概要
  • 肺がん
  • 乳がん
  • 前立腺がん
  • 悪性黒色腫
  • その他

プレシジョン免疫腫瘍学市場規模:治療タイプ別

  • 市場概要
  • チェックポイント阻害剤
  • CAR T細胞療法
  • がんワクチン
  • その他

プレシジョン免疫腫瘍学市場規模:バイオマーカー別

  • 市場概要
  • PD-L1
  • BRCA
  • KRAS
  • EGFR
  • その他

プレシジョン免疫腫瘍学市場規模:最終用途別

  • 市場概要
  • 病院
  • クリニック
  • 調査機関
  • その他

プレシジョン免疫腫瘍学市場規模

  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • スペイン
    • フランス
    • 英国
    • イタリア
    • その他欧州地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカ
    • ブラジル
    • その他ラテンアメリカ地域
  • 中東・アフリカ
    • GCC諸国
    • 南アフリカ
    • その他中東・アフリカ

競合情報

  • 上位5社の比較
  • 主要企業の市場ポジショニング(2024年)
  • 主な市場企業が採用した戦略
  • 市場の最近の動向
  • 企業の市場シェア分析(2024年)
  • 主要企業の企業プロファイル
    • 会社概要
    • 製品ポートフォリオ分析
    • セグメント別シェア分析
    • 収益の前年比比較(2022-2024)

主要企業プロファイル

  • Adaptimmune Therapeutics plc(UK)
  • Agenus Inc.(US)
  • Amgen Inc.(US)
  • AstraZeneca plc(UK)
  • Bristol Myers Squibb Company(US)
  • Celgene Corporation(US)
  • Eli Lilly and Company(US)
  • F. Hoffmann-La Roche Ltd.(Switzerland)
  • Gilead Sciences, Inc.(US)
  • GlaxoSmithKline plc(UK)
  • Iovance Biotherapeutics, Inc.(US)
  • Juno Therapeutics, Inc.(US)
  • Kite Pharma, Inc.(US)
  • Merck & Co., Inc.(US)
  • Neon Therapeutics, Inc.(US)
  • Novartis AG(Switzerland)
  • Pfizer Inc.(US)
  • Sanofi SA(France)
  • Seattle Genetics, Inc.(US)
  • Takeda Pharmaceutical Company Limited(Japan)

結論と推奨事項

目次
Product Code: SQMIG35H2063

Global Precision Immuno-Oncology Market size was valued at USD 60.65 billion in 2023 and is poised to grow from USD 67.20 billion in 2024 to USD 152.65 billion by 2032, growing at a CAGR of 10.8% during the forecast period (2025-2032).

Precision immuno-oncology is swiftly gaining traction as a pioneering approach in cancer treatment, focusing on tailored therapies that consider patients' genetic profiles, tumor characteristics, and immune responses. This personalized strategy not only enhances treatment efficacy but also minimizes side effects compared to conventional therapies, offering hope for long-term remissions. Advanced diagnostics play a crucial role in identifying unique genetic mutations and proteins on cancer cells, enabling targeted interventions. Clinical trials have demonstrated encouraging results, particularly in patients with treatment-resistant cancers, showcasing remarkable patient responses. The sector is witnessing substantial investment as pharmaceutical companies recognize the transformative potential of precision immuno-oncology, marking a significant milestone in the evolution of cancer care and highlighting its promising future in the market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Precision Immuno-Oncology market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Precision Immuno-Oncology Market Segmental Analysis

Global Precision Immuno-Oncology Market is segmented by cancer type, treatment type, biomarker, end use and region. Based on cancer type, the market is segmented into lung cancer, breast cancer, prostate cancer, melanoma and others. Based on treatment type, the market is segmented into checkpoint inhibitors, Car T Cell Therapy, cancer vaccines and others. Based on biomarker, the market is segmented into PD-L1, BRCA, KRAS, EGFR and others. Based on end use, the market is segmented into hospital, clinics, research institutes and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Precision Immuno-Oncology Market

The Global Precision Immuno-Oncology market is witnessing significant growth driven by the rising incidence of cancer worldwide. As cancer remains a pressing health issue, the need for advanced treatment options is becoming increasingly urgent. Traditional therapies like chemotherapy and radiation often have severe limitations and side effects, leading to a push for more innovative solutions. Precision immuno-oncology stands out by harnessing the body's immune system to combat cancer effectively. This tailored approach enables the development of targeted therapies based on individual genetic profiles, tumor characteristics, and immune responses, potentially enhancing treatment efficacy while minimizing adverse effects, thus propelling market demand.

Restraints in the Global Precision Immuno-Oncology Market

The Global Precision Immuno-Oncology market faces significant challenges primarily due to the high costs associated with these advanced therapies. Unlike traditional cancer treatments, precision immuno-oncology offers a personalized approach, which inherently involves complex and expensive methodologies. This heightened expense can restrict patient access, particularly for those in developing nations where healthcare resources are scarce. Factors such as exorbitant research and development expenditures, the requirement for specialized equipment, and the processes involved in biomarker testing further escalate costs. The unique treatment plans tailored for individual patients add another layer of expense, creating disparities in access to effective cancer care, especially for individuals from low- and middle-income regions, thereby exacerbating existing inequities in cancer treatment and outcomes.

Market Trends of the Global Precision Immuno-Oncology Market

The Global Precision Immuno-Oncology market is witnessing significant growth driven by the increasing adoption of combination therapies that integrate immunotherapy with traditional treatments like chemotherapy and radiation. This trend is rooted in the rising awareness of the enhanced treatment efficacy and the potential to combat drug resistance inherent in singular therapies. As research continues to yield promising results-especially in complex cancers such as lung cancer and melanoma-clinicians are increasingly leveraging these multi-faceted treatment approaches to improve patient outcomes. Furthermore, advancements in biomarker identification and personalized medicine are expected to further propel market expansion, catering to a more tailored cancer treatment landscape.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2024
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Pipeline Product Analysis
  • Case Study Analysis

Global Precision Immuno-Oncology Market Size by Cancer Type & CAGR (2025-2032)

  • Market Overview
  • Lung Cancer
  • Breast Cancer
  • Prostate Cancer
  • Melanoma
  • Others

Global Precision Immuno-Oncology Market Size by Treatment Type & CAGR (2025-2032)

  • Market Overview
  • Checkpoint Inhibitors
  • Car T Cell Therapy
  • Cancer Vaccines
  • Others

Global Precision Immuno-Oncology Market Size by Biomarker & CAGR (2025-2032)

  • Market Overview
  • PD-L1
  • BRCA
  • KRAS
  • EGFR
  • Others

Global Precision Immuno-Oncology Market Size by End Use & CAGR (2025-2032)

  • Market Overview
  • Hospital
  • Clinics
  • Research Institutes
  • Others

Global Precision Immuno-Oncology Market Size & CAGR (2025-2032)

  • North America (Cancer Type, Treatment Type, Biomarker, End Use)
    • US
    • Canada
  • Europe (Cancer Type, Treatment Type, Biomarker, End Use)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Cancer Type, Treatment Type, Biomarker, End Use)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Cancer Type, Treatment Type, Biomarker, End Use)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Cancer Type, Treatment Type, Biomarker, End Use)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2024
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2024
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

  • Adaptimmune Therapeutics plc (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Agenus Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Amgen Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca plc (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bristol Myers Squibb Company (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Celgene Corporation (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eli Lilly and Company (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • F. Hoffmann-La Roche Ltd. (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Gilead Sciences, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GlaxoSmithKline plc (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Iovance Biotherapeutics, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Juno Therapeutics, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Kite Pharma, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck & Co., Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Neon Therapeutics, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sanofi SA (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Seattle Genetics, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Takeda Pharmaceutical Company Limited (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations